Arca
Skip to content
Tools
Tools

Duloxetine Delayed-Release Capsules USP 30 mg

Recall D-0188-2025, part of FDA recall event 96074. See Rising Pharma Holdings's company page.

Rising Pharma Holding, Inc. started this Class II drug recall on Dec 30, 2024 (voluntary: firm initiated); FDA lists it as ongoing.

  • Classification: Class II
  • Started: Dec 30, 2024
  • Status: Ongoing
  • Products in this event: 3

Why It Was Recalled

Class II

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Record

Product
Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ
Quantity
42,527 bottles
Lots and codes
a) Lot# DT3023051A, exp. date Apr-25; b) DT3023025A, exp. date Jan-25
Distribution
Nationwide
Recalling firm
Rising Pharma Holding, Inc., East Brunswick, NJ, United States
How the firm notified
Letter
FDA classified
Jan 8, 2025

Other Products in This Recall

Recall event 96074

Rising Pharma Holding, Inc.'s Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.